The renal natriuretic actions of endogenous atrial natriuretic factor are enhanced by neutral endopeptidase inhibition (NEP-I). Recognizing that activation ofthe renin-angiotensin-aldosterone system in congestive heart failure (CHF) antagonizes the renal actions of atrial natriuretic factor, we hypothesized that angiotensin II antagonism with converting enzyme inhibition would potentiate the renal actions of NEP-I in CHF. To test this hypothesis, the renal responses to a specific NEP-I (SQ 28,603) were assessed in dogs with eight days of experimental CHF produced by rapid ventricular pacing. The renal natriuretic responses to NEP-I in experimental CHF were significant. In the same model of CHF, chronic angiotensin antagonism with converting enzyme inhibition potentiated both renal hemodynamic and excretory responses to NEP-I. The potentiated renal hemodynamic response included significant increases in glomerular filtration rate and filtration fraction. In the CHF group with angiotensin antagonism, an intrarenal infusion of low-dose angiotensin abolished the potentiated renal responses to NEP-I, supporting the concept that intrarenal angiotensin antagonism, rather than improved systemic hemodynamics or potentiation of other peptide systems, mediated the enhanced renal responses to NEP-I in the presence of converting enzyme inhibition. (J. Clin. Invest. 1991. 88:1636-1642 
Introduction
Atrial natriuretic factor (ANF)1 is a peptide hormone of cardiac origin with multiple biologic effects including natriuresis, diuresis, vasodilation, and inhibition of renin and aldosterone secretion. Among pathophysiologic states associated with ele-vated circulating ANF, some of the highest levels are seen in humans and animals with congestive heart failure (CHF) (1) . However, several studies (2-7) have demonstrated a blunted renal response to exogenous ANF in CHF. Multiple mechanisms have been implicated in this blunted renal response to ANF in CHF including: changes in ANF receptor density (8) (9) (10) , enhanced degradation and clearance of ANF (11, 12) , altered postreceptor signal transduction (13) , activation ofcounterregulatory neurohumoral systems (14, 15) , and decreased renal perfusion pressure (5) . These mechanisms are not mutually exclusive.
Accumulating evidence suggests that activation of the renin-angiotensin-aldosterone system (RAAS) in part contributes to sodium retention in CHF and renal resistance to ANF in this sodium avid state. In fact, previous studies have demonstrated antagonism between the RAAS and ANF with respect to both renal hemodynamics and tubular sodium handling (16, 17) . In general, ANF promotes sodium excretion and vasorelaxation while angiotensin II (All) promotes sodium retention and vasoconstriction. Moreover, in a recent study by Raya et al. (18) All inhibition with a converting enzyme inhibitor enhanced hemodynamic responsiveness to ANF in rats with CHF, and a preliminary report indicates that All inhibition restored the natriuretic response to infused ANF in dogs with high-output CHF (15) . In contrast, one recent study failed to demonstrate an association between RAAS activation and ANF resistance (19) . Thus, most available evidence suggests that activation of the RAAS antagonizes the renal actions of ANF in CHF.
ANF is degraded in vitro and in vivo by neutral endopeptidase (12, [20] [21] [22] . Recent studies from our laboratory have demonstrated that neutral endopeptidase inhibition (NEP-I) potentiates the renal action ofboth physiologic and pathophysiologic levels of ANF in normal anesthetized dogs (22) A flank incision was performed to gain exposure to the left kidney in all groups. The ureter was cannulated for urine collection and a noncannulating electromagnetic flow probe (Carolina Medical Electronics, Inc., King, NC) was placed around the renal artery for online measurement of renal blood flow. In group II, bilateral flank incisions were performed and both kidneys instrumented as described above. In addition, in all kidneys studied, curved 23-gauge needles, attached to polyvinyl tubing, were inserted into each renal artery distal to the flow probe and were kept patent by an infusion of0.9% saline at 0.5 ml/min.
Experimental protocol. A priming dose of inulin was given, and a constant infusion of I ml/min was begun in an effort to achieve a steady-state plasma level of40-60 mg/dl. Following a 60-min equilibration period, a sample ofarterial blood was drawn for baseline hormonal analysis. In group II an intrarenal infusion of All (1.5 ng/kg per min, Sigma Chemical Co., St. Louis, MO) was initiated into the right renal artery while the contralateral kidney and the instrumented kidney in group I received the saline vehicle at the same rate (0.5 ml/min). The dose ofAll was selected to produce pathophysiologic levels ofAll in the supplemented kidney without affecting systemic hemodynamics or renal function in the contralateral kidney (16) . After a 15-min lead in period, 30-min "pre-NEP-I" renal clearances were performed for all kidneys. During this and subsequent clearance periods, blood was drawn for hormonal analyses and determination ofinulin, sodium, and lithium concentrations. Cardiac output, mean arterial pressure, right and left atrial pressure, renal blood flow, and urine flow were also measured during each clearance period. Additional urine samples were collected on ice for measurement of urinary ANF and urinary cGMP.
At the conclusion of the pre-NEP-I clearance period, in all groups the NEP-I (SQ 28,603, Bristol-Myers-Squibb, Inc.) was given intravenously over 2 min at a dose of 30 mg/kg dissolved in 20 ml of 0.83% sodium bicarbonate solution. SQ 28, 603 Analysis. Cardiac output was determined by thermodilution (Cardiac Output model 9510-A computer, American Edwards Laboratories, Irvine, CA), measured in quadruplicate and averaged during each clearance period. Pulmonary capillary wedge pressure was used to determine left atrial pressure and right atrial pressure was measured directly. Systemic vascular resistance was calculated by dividing cardiac output by the difference between mean arterial and right atrial pressures. All voided urine was collected on ice, measured using a graduated cylinder, and aliquoted for measurement of sodium, inulin, lithium, ANF, and cGMP concentrations. Urine samples for ANF analysis were stored at -20'C until assay. Urine samples for cGMP determination were heated to > 90'C to eliminate phosphodiesterase activity and stored at -20'C until analysis.
Blood for sodium, creatinine, and lithium determination was collected in heparinized tubes, placed on ice, and centrifuged at 2,500 rpm at 4VC. After centrifugation, plasma was separated and refrigerated until analysis. Glomerular filtration rate (GFR) was determined by inulin clearance. Plasma and urine inulin concentrations were determined by the anthrone method (25) . To calculate renal filtration fraction, GFR was divided by renal plasma flow. Plasma and urinary sodium concentrations were measured using ion-selective electrodes (Beckman Instruments, Brea, CA), and plasma and urine lithium levels were determined by flame-emission spectrophotometry (model 357; Instrumentation Laboratory, Inc., Lexington, MA). Proximal fractional sodium reabsorption (Prox FRNa) was calculated using the formula: Prox FRNa (%) = [1 -(Li clearance/inulin clearance)] x 100. Distal fractional reabsorption of sodium (Dist FRNa) was calculated using the formula: Dist FRNa (%) = [(Li clearance-Na clearance)/(Li clearance)] X 100.
Blood for hormone analysis was placed in EDTA tubes, immediately placed on ice, and centrifuged at 2,500 rpm at 4°C. Plasma was separated and stored at -20°C until assay. Extracted arterial plasma levels of ANF and urinary ANF were measured by radioimmunoassay to a-hANF as previously described (1). Plasma renin activity was determined by radioimmunoassay using the method of Haber et al. (26) . Plasma aldosterone concentration was measured by specific radioimmunoassay (27) . Plasma samples for cGMP were extracted with ethanol. Plasma and urinary cGMP were measured by radioimmunoassay using the method of Steiner (28) . Fractional excretion of ANF was calculated by dividing the urinary clearance of ANF by the urinary clearance of inulin. Net renal generation of cGMP, a measure of nephrogenous cGMP production, was determined using the formula: Net renal generation of cGMP = (urinary cGMP X urine flow rate) -(plasma cGMP X GFR).
All data are presented as mean±standard error. Within each group, comparisons with baseline were made using analysis of variance for repeated measures followed by Dunnett's t test when appropriate. Comparisons between groups were analyzed by one-way analysis ofvariance followed by Fisher's least significant difference test when appropriate. Comparisons of absolute changes after NEP-I between kidneys in group II were analyzed by paired Student's t test. Statistical significance was defined as P < 0.05.
Results
At baseline, before initiation of intrarenal infusions, plasma renin activity was moderately but significantly increased in the captopril-treated group (n = 6) compared with untreated controls (n = 6) as illustrated in Fig. 1 . The systemic hemodynamic and hormonal parameters for the two experimental groups before and after NEP-I administration are presented in Table I . In the pre-NEP-I period, mean plasma ANF levels were lower with inhibition ofAII generation in group II, yet plasma cGMP levels did not differ between the two groups.
Renal hemodynamic and excretory parameters for the two experimental groups before and after NEP-I administration are presented in Table II . Before NEP-I administration, there were no significant differences in renal hemodynamic or excretory function between the CHF groups with and without inhibition of AII generation.
In CHF with NEP-I alone (group I), the only significant cardiac hemodynamic response to NEP-I was a decrease in right atrial pressure observed at one hour post-NEP-I. In addition, a significant increase in plasma ANF was observed after NEP-I administration (524±77 to 680±104 pg/ml), which returned towards baseline levels 1 h post-NEP-I. Plasma cGMP levels paralleled this response. Sustained decreases in tubular sodium reabsorption were observed after NEP-I administration in group I, as indicated by increases in fractional excretion of sodium and decreases in distal fractional sodium reabsorption. However, there were no significant renal hemodynamic responses to NEP-I.
In group II with CHF and inhibition of AII generation, there were no initial systemic hemodynamic responses to NEP-I administration, but a small decrease in cardiac output and increased systemic vascular resistance were observed 1 h post-NEP-I. In addition, a significant increase in plasma ANF was observed after NEP-I in group II (346±63 to 447±71 pg/ml), and plasma ANF levels tended to remain increased at 1 h post-NEP-I administration. Plasma cGMP levels increased initially after NEP-I then returned to baseline levels. In contrast to group I, significant renal hemodynamic changes were observed in the CHF group with CEI after NEP-I administration. Specifically, a 58.7% increase in GFR, a 9.9% decrease in renal blood flow, and a 91.7% increase in filtration fraction were observed in group II, and these changes tended to be sustained. Increases in urine flow, absolute sodium excretion, and fractional excre- (Fig. 2 ).
In the CHF group with inhibition ofendogenous All generation, low dose intrarenal All infusion had marked effects upon the initial renal responses to NEP-I as shown in Fig. 3 . In the All kidney, there was no GFR or filtration fraction response to NEP-I as was observed in the control kidney. In addition to the consequent reductions in filtered load of sodium, there was a significantly smaller decrease in distal nephron sodium reabsorption in the All infused kidney.
Discussion
The present studies were designed to test the hypothesis that chronic inhibition of AII generation during the evolution of experimental CHF potentiates the renal actions of NEP-I. These studies demonstrate that the renal natriuretic responses to NEP-I in experimental CHF are significant. However, in the same experimental model of CHF, chronic inhibition of All generation with converting enzyme inhibition in the absence of significant changes in systemic hemodynamics or renal func- tion at baseline, potentiated both renal hemodynamic and excretory responses to NEP-I. The potentiated renal hemodynamic response was associated with significant increases in GFR and filtration fraction which has not been observed previously in either normal subjects or in the setting of CHF. Finally, in the CHF group with CEI, an intrarenal infusion oflow dose All completely abolished the potentiated renal responses to NEP-I supporting the concept that intrarenal All inhibition, rather than improved systemic hemodynamics or potentiation of other peptide systems, mediated the enhanced renal responses to NEP-I in group II. We report, for the first time, the modulating role of the RAAS upon the renal actions of NEP-I in CHF. Importantly, the potentiating action oflow dose inhibition ofAll generation occurred despite a tendency towards reduced renal perfusion pressure, a parameter of profound functional importance for renal responses to ANF (5) . Analogously, Abassi et al. (17) demonstrated that CEI potentiated natriuretic responses to ANF in CHF despite significant decreases in renal perfusion pressure. Moreover, the observation that chronic inhibition of All generation did not significantly alter systemic hemodynamics at baseline compared with untreated CHF suggests that potentiation of NEP-I action was not simply a consequence of reducing the hemodynamic severity of CHF. Nevertheless, we did observe a 34% reduction in plasma ANF levels in the CHF (15) . The significant increase in plasma renin activity at baseline in the group treated with captopril supports a significant, though probably not complete, inhibition of angiotensin converting enzyme. Finally, our finding that inhibition of All generation did not significantly alter baseline sodium excretion in severe CHF is consistent with some (17) but not all (7, 29) previous studies, and again could reflect a partial degree of converting enzyme inhibition. Despite the relatively lower plasma ANF levels in the captopril-treated animals with CHF, baseline plasma cGMP levels did not differ between the two groups. One possible explanation is that the renin angiotensin aldosterone system activation in CHF is impairing cGMP generation in congestive heart failure. In fact, a recent study (13) demonstrates that despite steadily increasing plasma ANF concentrations, plasma cGMP levels plateau during the evolution of experimental heart failure in association with progressive increases in plasma renin activity. Moreover, an elegant in vitro study by Smith and Lincoln (30) demonstrates that angiotensin II mediated increases in intracellular phophodiesterases may impair ANF mediated increases in cyclic GMP. Thus, it is conceivable that the increased ratio of plasma ANF to plasma cyclic GMP before NEP-I in group II is related to attenuation of angiotensin II generation by captopril.
The enhanced natriuretic response to NEP-I in CHF with inhibition of All generation is consistent with the concept that the renal actions of NEP-I, like those of ANF, are antagonized by activation ofthe RAAS in CHF. The multilevel antinatriuretic effects of All are well established and include direct or indirect effects on multiple nephron segments (31) . In recent years, a multilevel functional antagonism between the RAAS and ANF has emerged, particularly with respect to sodium excretion. Studies by Appel et al. (32) demonstrate that ANF, and its intracellular second messenger cGMP, dose-dependently antagonize AII-mediated mesangial cell contraction. In addition, Showalter et al. ( 16) observed that low dose intrarenal All attenuates ANF-mediated changes in both GFR and tubular sodium reabsorption in the normal dog, while the studies of Abassi et al. (17) indicate that CEI restores tubular responses to ANF in rats with CHF. Studies by Salazar et al. (33) suggest that All antagonizes ANF induced decreases in proximal tubule reabsorption. In the present studies potentiation of the natriuretic actions of NEP-I with inhibition of All generation occurred in the absence of any decreases in whole kidney proximal fractional sodium reabsorption, as determined by lithium clearance, suggesting that CEI did not potentiate NEP-I induced natriuresis at the level of the proximal tubule.
We observed that CEI greatly potentiated the renal hemodynamic actions of NEP-I. In previous studies, NEP-I produced no significant changes in whole kidney renal hemodynamics in normal animals (22) or in those with untreated CHF ( 12). However, in the presence of chronic CHF and inhibition of the generation ofAll, marked increases in GFR and filtration fraction and modest decreases in renal blood flow were observed. Recent studies demonstrating that the renal effects of NEP-I are virtually abolished in the presence ofmonoclonal anti-ANF antibodies (34) , support the concept that the renal actions of NEP-I are largely mediated via ANF potentiation. Consequently, the known renal hemodynamic actions of ANF suggest several possible mechanisms for the potentiated renal hemodynamic effects ofNEP-I in CHF with CEI. As ANF attenuates and All enhances whole kidney tubuloglomerular feedback responses (35, 36) , inhibition of All might potentiate ANF-or NEP-I-mediated increases in GFR via tubuloglomerular feedback inhibition. This mechanism may be particularly important in CHF where GFR responses to increases in distal nephron solute delivery are intact or even accentuated (35, 37) . In addition, ANF increases GFR and filtration fraction via decreases in afferent arteriolar resistance and increases in efferent arteriolar resistance (38) . The latter effect upon efferent resistance may be enhanced in the presence of inhibition of All which should decrease basal efferent tone (39 In both experimental groups significant increases in fractional excretion ofANF were observed following NEP-I in association with increases in distal fractional reabsorption of sodium. These observations support the concept that blocking proximal degradation ofANF with NEP-I allows intact ANFto reach the distal nephron (1 1, 34) , specifically the inner medullary collecting duct where ANF receptors are abundant (43) . Recent studies by Sonnenberg et al. (44) The NEP-I used in this study, SQ 28,603, has minimal activity against other proximal tubule brush border enzymes; however, neutral endopeptidase itself hydrolyzes several peptides other than ANF in vitro, including kinins, angiotensins, enkephalins, neurotensin, substance P, insulin B-chain, and endothelin (45) . Because angiotensin converting enzyme degrades kinins in vivo, the renal and systemic actions of kinins might be doubly potentiated by NEP-I in the presence of chronic CET. In regard to these theoretical considerations and recent studies by Smits et al. (46) suggesting that kinins participate in the potentiation of ANF activity by NEP-I, we cannot exclude a role for kinins in the potentiated renal responses to NEP-I in the CHF group with All inhibition. Similarly, although renal blood flow was not significantly different in groups I and II before NEP-I, we cannot exclude that a vasodilator effect independent of All antagonism contributed to the enhanced renal responses. Nevertheless, in group II, the reversal of all potentiated renal responses to NEP-I with low dose intrarenal All supports the concept that the potentiated renal hemodynamic and tubular responses to NEP-I in CHF were primarily related to All inhibition rather than kinin potentiation or nonspecific hemodynamic alterations.
In conclusion, the present studies confirm previous investigations by demonstrating that, in anesthetized dogs in the presence of experimental CHF, the natriuretic effects of NEP-I occur principally via decreases in tubular sodium reabsorption independent of significant alterations in GFR or renal blood flow. The present studies extend previous investigations by demonstrating that, in moderately severe CHF, chronic inhibition of All generation potentiates the renal hemodynamic and tubular responses to NEP-I in CHF. Finally, low dose intrarenal All abolished the potentiated responses to NEP-I suggesting that All inhibition, rather than systemic hemodynamic factors or modulation of other peptide systems, participate in the enhanced renal responses to NEP-I in CHF treated with chronic converting enzyme inhibition. Because chronic converting enzyme inhibition has proven efficacious in humans with moderately severe CHF (47) , these studies suggest a possible therapeutic role for adjuvant therapy with NEP-I in human CHF associated with renal decompensation. decompensation.
